ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.
Angiotensin-Converting Enzyme 2
Betacoronavirus
Biomarkers, Tumor
COVID-19
Carcinoma, Renal Cell
/ immunology
Coronavirus Infections
/ immunology
Endometrial Neoplasms
/ immunology
Female
Humans
Immunity, Cellular
Kidney Neoplasms
/ immunology
Pandemics
Peptidyl-Dipeptidase A
/ biosynthesis
Pneumonia, Viral
/ immunology
Prognosis
SARS-CoV-2
ACE2
COVID-19
SARS-CoV-2
immune infiltration
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
27 Apr 2020
27 Apr 2020
Historique:
received:
11
03
2020
accepted:
04
04
2020
pubmed:
28
4
2020
medline:
7
5
2020
entrez:
28
4
2020
Statut:
ppublish
Résumé
Angiotensin-converting enzyme 2 (ACE2) is a member of the renin-angiotension system, however, the correlation between ACE2 and prognosis in UCEC (Uterine Corpus Endometrial Carcinoma) and KIRP (Kidney Renal Papillary Cell Carcinoma) is not clear. We analyzed the expression levels of ACE2 in the Oncomine and TIMER databases, the correlation between ACE2 and overall survival in the PrognoScan, GEPIA and Kaplan-Meier plotter databases. The correlation between ACE2 and immune infiltration level and the type markers of immune cells was investigated in TIMER database. A prognosis analysis based on the expression levels of ACE2 was further performed in related immune cells subgroup. The ACE2 promoter methylation profile was tested in the UALCAN database. In addition, we used GSE30589 and GSE52920 databases to elucidate the changes of ACE2 expression in vivo and in vitro after SARS-CoV infection. ACE2 was elevated in UCEC and KIRP, and high ACE2 had a favorable prognosis. The expression of ACE2 was positively correlated with the level of immune infiltration of macrophage in KIRP, B cell, CD4+T cell, neutrophil and dendritic cell immune infiltration levels in UCEC. ACE2 was significantly positively correlated with the type markers of B cells and neutrophils, macrophages in UCEC, while ACE2 in KIRP was positively correlated with the type markers of macrophages. High ACE2 expression level had a favorable prognosis in different enriched immune cells subgroups in UCEC and KIRP. And the promoter methylation levels of ACE2 in UCEC and KIRP were significantly reduced. What's more, we found that the expression of ACE2 decreased in vivo and in vitro after SARS-CoV infection. In conclusion, ACE2 expression increased significantly in UCEC and KIRP, elevated ACE2 was positively correlated with immune infiltration and prognosis. Moreover, tumor tissues may be more susceptible to SARS-CoV-2 infection in COVID-19 patients with UCEC and KIRP, which may worsen the prognosis.
Identifiants
pubmed: 32339157
pii: 103100
doi: 10.18632/aging.103100
pmc: PMC7202533
doi:
Substances chimiques
Biomarkers, Tumor
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6518-6535Références
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Neoplasia. 2007 Feb;9(2):166-80
pubmed: 17356713
Eur J Obstet Gynecol Reprod Biol. 2013 Jul;169(1):1-9
pubmed: 23433742
Am J Pathol. 1998 Nov;153(5):1467-73
pubmed: 9811338
Endocr Relat Cancer. 2009 Jun;16(2):363-80
pubmed: 19190080
Oncol Rep. 2016 Sep;36(3):1403-10
pubmed: 27460845
Inflamm Res. 2015 Apr;64(3-4):253-60
pubmed: 25721616
J Exp Clin Cancer Res. 2019 Apr 25;38(1):173
pubmed: 31023337
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Vasa. 2014 Nov;43(6):404-14
pubmed: 25339158
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Nat Rev Genet. 2005 Aug;6(8):597-610
pubmed: 16136652
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Int J Mol Med. 2018 Jan;41(1):409-420
pubmed: 29138810
Europace. 2017 Aug 1;19(8):1280-1287
pubmed: 27738071
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Clin Cancer Res. 2016 Dec 15;22(24):6236-6246
pubmed: 27256309
Cancer Sci. 2019 May;110(5):1564-1572
pubmed: 30861269
Mod Pathol. 1997 Jun;10(6):537-44
pubmed: 9195569
Cancer Lett. 2011 Aug 1;307(1):18-25
pubmed: 21481527
Cancer Lett. 2016 Jul 1;376(2):268-77
pubmed: 27063099
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
BMC Med Genomics. 2009 Apr 24;2:18
pubmed: 19393097
Nat Genet. 2000 Feb;24(2):132-8
pubmed: 10655057
Crit Rev Oncol Hematol. 2015 Oct;96(1):100-12
pubmed: 26052049
J Renin Angiotensin Aldosterone Syst. 2012 Mar;13(1):202-9
pubmed: 22048948
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Nat Rev Genet. 2012 Oct;13(10):679-92
pubmed: 22945394
Clin Cancer Res. 2017 Aug 1;23(15):4473-4481
pubmed: 28264871
Oncol Rep. 2010 Apr;23(4):941-8
pubmed: 20204277
J Mol Histol. 2014 Feb;45(1):47-57
pubmed: 23921915
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Biol Chem. 2000 Oct 27;275(43):33238-43
pubmed: 10924499
Histopathology. 2013 Sep;63(3):309-15
pubmed: 23802739
Surg Pathol Clin. 2019 Jun;12(2):343-362
pubmed: 31097108